NEO

Neogenomics Inc Industrials Services-Testing Laboratories Russell 3000
$17.38Close $2.2BMarket cap $7.19 – $19.9152-week range Late-januaryNext report · estimated

Highlights

Strengths

  • Leading the market RS 92 · stronger than 92% of stocks over 12 months

Cautions

  • Trend not confirmed 7 of 8 conditions · under the 50-day

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Oct 28, 2026
Off 12-month high 13%
1wk up 4.8% price change
1mo down 5.3% price change
12-month return up 79% market up 11% · its own up 58%
F-score 4 / 9 Weak
Altman Z″ 1.46 Moderate risk
P/E — price / earnings
PEG — P/E / EPS growth
P/B 2.7× price / book
Earnings yield down 4.8% EBIT / enterprise value
Cheaper than 31% of the market · expensive
Revenue growth up 10% year on year
EPS growth — latest quarter
Sales growth up 11% latest quarter · +0 pts
ROE down 12% return on equity
Free cash margin down 3% -$21.8M FCF
D/E 0.41 long-term debt / equity
Net debt / EBITDA —
Interest cover —EBIT / interest
Piotroski tests
  • not yet profitable on its assets
  • profitability slipped from last year
  • took on more long-term debt
  • issued more shares
  • gross margin narrowed
  • generating cash from operations
  • profits backed by cash
  • short-term liquidity improved
  • assets working harder

Trade setup

ATR% 5.1% $0.89 a day · 2×ATR $15.61
RS 92 / 99 vs the universe
Trend 7 / 8 under the 50-day
Relative volume 0.7× vs 50-day average
Up/down volume 1.06 50 sessions
Implied move — no scheduled report
Trend template · 7 of 8
  • Price above the 50-day average: fails

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Oct 28, 2026
Last shock Oct 6, 2026-14% in one session2.3× volumeon results+5% since

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $727.3M +10% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $444.4M FY2021 · $484.3M FY2022 · $509.7M FY2023 · $591.6M FY2024 · $660.6M FY2025 · $727.3M
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$108.0M
-$200M $0 FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $4.2M FY2021 · -$8.0M FY2022 · -$144.0M FY2023 · -$88.0M FY2024 · -$79.0M FY2025 · -$108.0M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$21.8M
-$100M $0 FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$27.6M FY2021 · -$90.9M FY2022 · -$96.9M FY2023 · -$30.7M FY2024 · -$34.0M FY2025 · -$21.8M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 43%
  • Net -15%
  • Free cash -3%
-50% 0% 50% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 42% · Net 1% · Free cash -6% FY2021 · Gross 39% · Net -2% · Free cash -19% FY2022 · Gross 37% · Net -28% · Free cash -19% FY2023 · Gross 41% · Net -15% · Free cash -5% FY2024 · Gross 44% · Net -12% · Free cash -5% FY2025 · Gross 43% · Net -15% · Free cash -3%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $182.2M net debt
  • Cash
  • Long-term debt
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $228.7M · Long-term debt $171.9M FY2021 · Cash $316.8M · Long-term debt $533.7M FY2022 · Cash $263.2M · Long-term debt $535.4M FY2023 · Cash $342.5M · Long-term debt $538.2M FY2024 · Cash $367.0M · Long-term debt $340.3M FY2025 · Cash $159.6M · Long-term debt $341.9M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 128.99m +15.1% since FY2020
128.99m 112.08m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 112.08m FY2021 · 124.11m FY2022 · 126.91m FY2023 · 127.37m FY2024 · 128.15m FY2025 · 128.99m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $444.4M $484.3M $509.7M $591.6M $660.6M $727.3M
Gross margin 42% 39% 37% 41% 44% 43%
Operating income -$14.0M -$118.8M -$157.6M -$107.7M -$92.1M -$115.9M
Net income $4.2M -$8.0M -$144.0M -$88.0M -$79.0M -$108.0M
Net margin 1% -2% -28% -15% -12% -15%
Earnings per share $0.04 -$0.07 -$1.16 -$0.70 -$0.62 -$0.84
Free cash flow -$27.6M -$90.9M -$96.9M -$30.7M -$34.0M -$21.8M
Free cash margin -6% -19% -19% -5% -5% -3%
Cash $228.7M $316.8M $263.2M $342.5M $367.0M $159.6M
Long-term debt $171.9M $533.7M $535.4M $538.2M $340.3M $341.9M
Shareholders' equity $694.3M $1.1B $998.0M $941.5M $902.3M $836.6M
Shares outstanding 112.08m 124.11m 126.91m 127.37m 128.15m 128.99m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Oct 28, 2026 Quarterly ↗ Sep 30, 2026 28d
Jul 28, 2026 Quarterly ↗ Jun 30, 2026 28d
Apr 28, 2026 Quarterly ↗ Mar 31, 2026 28d
Feb 17, 2026 Annual ↗ Dec 31, 2025 48d
Oct 28, 2025 Quarterly ↗ Sep 30, 2025 28d
Jul 29, 2025 Quarterly ↗ Jun 30, 2025 29d
Apr 29, 2025 Quarterly ↗ Mar 31, 2025 29d
Feb 18, 2025 Annual ↗ Dec 31, 2024 49d
Nov 5, 2024 Quarterly ↗ Sep 30, 2024 36d
Jul 30, 2024 Quarterly ↗ Jun 30, 2024 30d
Apr 30, 2024 Quarterly ↗ Mar 31, 2024 30d
Feb 20, 2024 Annual ↗ Dec 31, 2023 51d

Current reports